Related Experiment Video

Updated: Oct 7, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Oncostatic activity of a thiazolidinedione derivative on human androgen-dependent prostate cancer cells

R M Moretti1, M Montagnani Marelli, M Motta

  • 1Center for Endocrinological Oncology, Department of Endocrinology, University of Milano, Via Balzaretti 9, 20133 Milan, Italy.

International Journal of Cancer
|May 8, 2001
PubMed

Insights

The antiarthritic drug CGP 52608, a thiazolidinedione derivative, inhibits prostate cancer cell proliferation. It affects cell cycle progression by modulating cell cycle-related gene expression, potentially via RORalpha activation.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Oncology

Background:

  • Thiazolidinedione derivatives, like CGP 52608, show antiarthritic activity.
  • Their mechanism may involve activating the RORalpha nuclear receptor.
  • RORalpha response elements are found in cell cycle-related genes (p21(WAF1/CIP1), cyclin A).

Purpose of the Study:

  • To investigate if CGP 52608 affects cell proliferation, cell cycle, and gene expression in prostate cancer cells.
  • To test the hypothesis that CGP 52608 impacts cell cycle regulation via RORalpha.

Main Methods:

  • Treatment of human androgen-dependent prostate cancer LNCaP cells with CGP 52608.
  • Assessment of cell proliferation, cell cycle distribution, and expression of p21(WAF1/CIP1) and cyclin A.

Main Results:

  • CGP 52608 significantly decreased LNCaP cell proliferation in a dose-dependent manner.
  • It induced G0/G1 phase arrest and reduced S phase population.
  • Expression of p21(WAF1/CIP1) increased, while cyclin A expression decreased.

Conclusions:

  • CGP 52608 exhibits potent cytostatic activity in LNCaP prostate cancer cells.
  • This activity involves reduced proliferation and altered cell cycle distribution.
  • The effects are mediated by modulating cell cycle gene expression, possibly through RORalpha activation.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...